|
Malignant neoplasm of lung
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> The expression of HUWE1 and p53 in lung cancer cells was modulated and the phenotypes were assessed by performing soft agar colony forming assays, cell cycle analysis, BrdU incorporation assays, and xenograft tumor growth assays.
|
30026863 |
2018 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
2-anilino-4-amino-5-aroylthiazole-type compound AS7128 inhibits lung cancer growth through decreased iASPP and p53 interaction.
|
29285847 |
2018 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
53BP1 and TP53 gene interactions were not associated with lung cancer risk.
|
24316395 |
2014 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines.
|
12071807 |
2002 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations.
|
10100998 |
1999 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
Lung cancer studies of p53 and smoking need to consider the effect of histotype, and prognostic studies of p53 should adjust for the effects of T and N or stage and histotype.
|
10428201 |
1999 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer is difficult to control locally by radiotherapy and is known to have frequently p53 mutations.
|
14712319 |
2003 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Lung cancers frequently possess other defects in genes in the DNA damage response pathway (e.g. p53 mutations) and have a high level of genotoxic DNA damage induced by tobacco smoke.
|
18281249 |
2008 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation spectrum in lung cancer is not different in women and men.
|
15824188 |
2005 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.
|
15958551 |
2005 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis.
|
19623649 |
2009 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations have been found in most patients with non-small cell lung cancer (NSCLC), whereas PTEN mutations are rarely found in lung cancer, though most NSCLCs lack PTEN protein synthesis.
|
22489661 |
2012 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations and lung cancer: not all mutations are created equal.
|
24916693 |
2014 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population.
|
25921167 |
2015 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 gene status is a critical determinant of phenotypes induced by ALKBH3 knockdown in non-small cell lung cancers.
|
28479246 |
2017 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 is frequently involved in lung cancer development with polymorphic sites potentially having a role in it.
|
29286914 |
2018 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 and K-ras mutations are two of the major genetic alterations in human nonsmall cell lung cancers.
|
30873587 |
2019 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
|
31100334 |
2019 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations with 0.05-1.0% VAF were more prevalent (p < 0.05) and also enriched for tobacco smoke and age-associated mutation signatures in normal AEC from lung cancer cases compared to non-cancer controls matched for smoking and age.
|
31711466 |
2019 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A chemical mismatch cleavage method useful for the detection of point mutations in the p53 gene in lung cancer.
|
2223098 |
1990 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A distinct spectrum was observed, however, in the p53 mutation pattern in the two types of lung cancer.
|
12711114 |
2003 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A high frequency of somatic mutations in p53 (44.3%; 43/97) and/or EGFR (51.5%; 50/97) resulted in a high discrimination rate of tumor clonality (77.3%; 75/97) in metachronous multiple lung cancers.
|
24368645 |
2014 |
|
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
A human lung cancer cell line that expresses the temperature sensitive murine p53 was utilized to quantitate mRNA levels of various genes at different time points after shifting the temperature to 32 degrees C. Inhibition of protein synthesis by cycloheximide (CHX) was used to distinguish between primary and secondary target genes regulated by p53.
|
11402317 |
2001 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
A member of the p53 family, p73 may play an important role in the development of lung cancer.
|
17136456 |
2006 |